gastrointestinal stromal tumor
Conditions
Brief summary
Part 2: PFS (defined as the time from randomization to disease progression or death from any cause, whichever occurs first) as determined by BICR using mRECIST v1.1
Detailed description
Part 2 (key sec.): OS, defined as the time from randomization until the date of death, Part 2 (key sec.): ORR, as determined by BICR using mRECIST v1.1
Interventions
DRUGCGT9486
DRUGSUNITINIB
Sponsors
Cogent Biosciences Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part 2: PFS (defined as the time from randomization to disease progression or death from any cause, whichever occurs first) as determined by BICR using mRECIST v1.1 | — |
Secondary
| Measure | Time frame |
|---|---|
| Part 2 (key sec.): OS, defined as the time from randomization until the date of death, Part 2 (key sec.): ORR, as determined by BICR using mRECIST v1.1 | — |
Countries
Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Spain, Sweden
Outcome results
None listed